AHA comments to DEA on 2019 controlled substances quotas
The AHA Aug. 28 urged the Drug Enforcement Administration to reconsider its proposed 2019 aggregate production quotas for certain controlled substances, which the agency said would reduce manufacturing quotas for six frequently misused opioids by an average 10 percent. “Hospitals and other providers are currently facing critical shortages of a number of injectable opioid medications for which that the DEA recommends quota reductions, including morphine, hydromorphone, and fentanyl,” AHA said in a letter to DEA. “These decreases would exacerbate these already dire shortages.” AHA said its request is “specific to these injectable medopications and does not extend to other dosage forms or opioid products.” Comments are due Sept. 19.
Related News Articles
Headline
ASHP tracked a record 323 active drug shortages during the first quarter of 2024, surpassing the previous record of 320 shortages in 2014.“Some of the most…
Headline
The Department of Health and Human Services April 2 released a white paper proposing policy solutions for Congress and others to prevent drug shortages and…
Headline
In a statement submitted to the House Ways and Means Committee for a hearing Feb. 6 on chronic drug shortages, AHA recommended Congress enact legislation to…
Headline
Reps. Doris Matsui, D-Calif., and Larry Bucshon, R-Ind., Jan. 12 introduced a House version of the Mapping America’s Pharmaceutical Supply Act, legislation…
Headline
In a statement submitted to the Senate Finance Committee Dec. 5 for a hearing on drug shortages and potential health policy solutions, AHA reiterated its…
Headline
Oct. 28 is National Prescription Drug Take Back Day, an opportunity for the public to safely dispose of unwanted or expired tablets, capsules, patches and…